We have updated our terms and conditions and privacy policy
Click “Continue” to accept and continue with ET HealthWorld
Dear user,
ET HealthWorld privacy and cookie policy has been updated to align with the new data regulations in European Union. Please review and accept these changes below to continue using the website.
You can see our privacy policy & our cookie policy. We use cookies to ensure the best experience for you on our website.
If you choose to ignore this message, we’ll assume that you are happy to receive all cookies on ET HealthWorld.
Intercept to go back to FDA with its NASH treatment application
US FDA likely to okay clinical trials for pig-to-human organ transplants
Rebooting Cancer Awareness
The unsung hero in faster holistic recovery
Technological Disruption in Indian Health & Pharma
Do you think you are up for the challenge?
Holistic Solutions For A Healthier India
17 July
Adopting-Dynamic-Technologies
Knee osteoarthritis is a leading cause of disability among older people, the study said, citing 2020 research which found that more than 560 million people suffer from the condition worldwide.
Recommended by Colombia
125000+ Industry Leaders read it everyday
The growing anti-diabetes market, valued at about Rs 17,000 crore, is set to witness action with generic versions of US firm Merck’s blockbuster Januvia being launched, reducing the cost of therapy by a third. This is on the heels of Sitagliptin, a relatively newer but vital anti-diabetic drug, losing patent protection in July.
The Tamil Nadu Medical Services Corporation has blacklisted Abbott Healthcare for five years for hiding the fact that it has been banned by Directorate General of Health Services and Employees’ State Insurance Corporation.
We have various options to advertise with us including Events, Advertorials, Banners, Mailers, Webinars etc.
Please contact us to know more details.
Get ETHealthworld‘s top stories every morning in your email inbox.
125000+ Industry Leaders read it everyday
Follow @ETHealthworld for the latest news, insider access to events and more.
